References
- Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol 1995; 46: 83–96
- Blasi J, Chapman E, Link E, Binz T, Yamasaki S, Camilli P D, Sudhof T, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160–163
- Dolly J, de Paiva A, Foran P, Lawrence G, Daniels-Holgate P, Ashton A. Probing the process of transmitter release with botulinus and tetanus neurotoxin. Semin Neurosci 1944; 6: 149–158
- Borodic G, Ferrante R, Pearce L, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injection. Mov Disord 1994; 9: 31–39
- Boyd R N, Pliatsios V, Starr R, Wolfe R, Graham H K. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 2000; 42: 32–41
- Sutherland D H, Kaufman K R, Wyatt M P, Chambers H G. Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: A 3-dimensional motion analysis study. Gait Posture 1996; 4: 269–279
- Cosgrove A P, Corry I S, Graham H K. Botulinum Toxin in the management of the lower limb in cerebral palsy. Develop Med Child Neurol 1994; 36: 386–396
- Zurcher A W, Molenaers G, Desloovere K, Fabry G. Kinematic and kinetic evaluation of the ankle after intramuscular injection of botulinum toxin A in children with cerebral palsy. Acta Orthop Belg 2001; 67: 475–480
- Metaxiotis D, Siebel A, Doederlein L. Repeated botulinum toxin A injections in the treatment of spastic equinus foot. Clin Orthop 2002; 394: 177–185
- Papadonikolakis A S, Vekris M D, Korompilias A V, Kostas J P, Ristanis S E, Soucacos P N. Botulinum A toxin for treatment of lower limb spasticity in cerebral palsy: Gait analysis in 49 patients. Acta Orthop Scand 2003; 74: 749–755
- Sutherland D H, Kaufman K R, Wyatt M P, Chambers H G, Mubarak S J. Double blind study of botulinum toxin A injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999; 10: 1–9
- Hesse S, Brandl-Hesse B, Seidel U, Doll B, Gregoric M. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A. Restor Neurol Neurosci 2000; 17: 1–8
- Galli M, Crivellini M, Santambrogio G C, Fazzi E, Motta F. Short-term effects of “botulinum toxin” a as treatment for children with cerebral palsy: Kinematic and kinetic aspects at the ankle joint. Funct Neurol 2001; 16: 317–323
- Ferrigno G, Pedotti A. ELITE: a digital dedicated hardware system for movement analysis via real-time TV signal processing. IEEE Trans Biomed Eng 1985; 32: 943–950
- Davis R B, Ounpuu S, Tyburski D J, Gage J R. A gait analysis data collection and reduction technique. Hum Mov Sci 1991; 10: 575–587
- Koman L A, Mooney J F, III, Smith B, Goodman A. Management of cerebral palsy with botulinum toxin A: Preliminary investigation. J Paediatr Orthop 1993; 13: 489–495
- Olney S J, MacPhail H E, Hedden D M, Boyce W F. Work and power in hemiplegic cerebral palsy gait. Phys Ther 1990; 70: 431–438